Association between hyperlipidemia and prostatic enlargement: A case-control study

Abstract

Objective:

A high-fat diet is associated with the development of benign prostatic enlargement (BPE), but whether hyperlipidemia is associated with BPE remains unclear. This study aimed to evaluate whether hyperlipidemia is a risk factor for the development of BPE.

Material and methods:

This study included 265 BPE patients with lower urinary tract symptoms (LUTS) and 248 age-matched healthy individuals without LUTS. The patient and control groups included in the study were compared in terms of fasting serum glucose, serum lipid values, prostate specific antigen (PSA), and prostate size measured by abdominal ultrasonography.

Results:

The prostate sizes of the patient and healthy control group were 59.4 ± 12.6 and 41.8 ± 11.1 ml, respectively (p = 0.007). It was observed that the mean PSA value of the patient group (2.33 ± 1.69) was statistically higher than that of the control group (1.21 ± 1.05) (p = 0.002). Total cholesterol and LDL-cholesterol were significantly higher and HDL-cholesterol was significantly lower among the patients compared to the controls. Prostate size had a negative correlation with HDL-cholesterol and a positive correlation with LDL-cholesterol and total cholesterol. Additionally, LDL-cholesterol and total cholesterol were independent risk factors for prostate enlargement.

Conclusion:

This study indicates that increased levels of LDL-cholesterol and total cholesterol are significantly associated with the enlargement of the prostate. Hyperlipidemia may be one of the risk factors in the processes of prostatic growth and progression.

Keywords

Hyperlipidemia benign prostate enlargement lipid lower urinary tract symptoms aging

Get full access to this article

View all access options for this article.

References

Egan

KB.

The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016; 43: 289–297.

Robertson

Link

CL.

The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 347–354.

Zhang

Zeng

Liu

, et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014; 93(2): 214–219.

Zou

Gong

Fang

, et al. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016; 34(2): 281–289.

Nandeesha

Koner

Dorairajan

, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370(1–2): 89–93.

Parsons

Bergstrom

Barrett-Connor

Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008; 101: 313–318.

Jacobsen

Girman

Lieber

MM.

Natural history of benign prostatic hyperplasia. Urology 2001; 58: 5–16.

Patel

Feng

Simon

, et al. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer Prostatic Dis 2018; 21(2): 238–244.

De Nunzio

Aronson

Freedland

, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560–570.

10.

Alberti

Eckel

Grundy

, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645.

11.

Dahle

Chokkalingam

Gao

, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599–604.

12.

Nandy

Saha

Association between components of metabolic syndrome and prostatic enlargement: an Indian perspective. Med J Armed Forces India 2016; 72(4): 350–355.

13.

Robert

Descazeaud

Nicolaïew

, et al. A Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009; 69(16): 1774–1780.

14.

Corona

Vignozzi

Rastrelli

, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014; 2014: 329456.

15.

Biwa

Sakai

Shichiri

, et al. Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized low density lipoprotein-induced macrophage proliferation. J Atheroscler Thromb 2000; 7: 14–20.

16.

Nickel

Roehrborn

O’Leary

, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379–1384.

17.

Roehrborn

CG.

Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 2008; 10(1): 14–25.

18.

Di Silverio

Gentile

De Matteis

, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164–175.

19.

Vignozzi

Gacci

Cellai

, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73: 789–800.

20.

Zhuang

Lin

, et al. Cholesterol-rich lipid rafts mediate AKT-regulated survival in prostate cancer cells. Cancer Res 2002; 62(8): 2227–2231.

21.

Hammarsten

Högstedt

Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–158.

22.

Lekili

Muezzinoglu

Uyanik

, et al. Serum lipid levels in benign prostatic hyperplasia. World J Urol 2006; 24: 210–213.

23.

Stamatiou

Zaglavira

Skolarikos

, et al. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 2008; 34: 555–561.

24.

Marino

Pugno

Cevoli

, et al. Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 1991; 43(4): 279–282.